AUS
NZ
UK
CA
USA
IND
On Tuesday, Berenberg upgraded Hikma Pharmaceuticals (LSE:HIK), raising the price target from 2,100p to 2,400p, citing significant progress within the company. After nearly two years of maintaining a neutral stance, Berenberg now sees it as an opportune moment to revise the outlook on Hikma's stock.
The bank highlighted a strengthened growth outlook across various segments of Hikma’s business, including its US Generics division. This renewed confidence is bolstered by recent leadership changes, which have brought more stability and clarity to the company’s direction. Among these changes are the appointment of a new permanent CEO, who has a deep understanding of the company from an internal position, and the hiring of new leadership for both the Injectables and US Generics divisions.
Berenberg also emphasized Hikma's robust financial health, noting a strong balance sheet with leverage at 1.3x. The company’s financial position is further supported by substantial resources available for mergers and acquisitions, as evidenced by the recent acquisition of Xellia Pharmaceuticals. This financial stability is a key factor in the positive reassessment of Hikma’s prospects.
Additionally, Berenberg pointed to the company’s consistent performance in terms of return on invested capital, which has averaged 16% over the past three years. This strong track record underscores Hikma's ability to generate substantial returns, positioning it favorably within the industry.
The bank also noted that, given this context, the current valuation of 11.8x price-to-earnings appears reasonable. The valuation, coupled with the company's strong operational performance and leadership stability, indicates a positive outlook for Hikma going forward.
At 0915 BST, Hikma’s shares reflected this positive sentiment, rising by 1.8% to 2,010p. The upgrade and increased price target signal a renewed confidence in Hikma Pharmaceuticals, as the company continues to navigate its growth trajectory with enhanced leadership and financial strength. The combination of these factors suggests a solid foundation for future progress, with the company well-positioned to capitalize on upcoming opportunities in the pharmaceutical sector.
